Peptide library / Brain & sleep / NNZ-2591
NNZ-2591
An investigational synthetic analog of a natural brain peptide, in development for rare neurodevelopmental disorders.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Phelan-McDermid syndromeSmall human studies
- Angelman and Pitt-Hopkins syndromesSmall human studies
How it is thought to work
NNZ-2591 is a modified version of a small cyclic peptide made when IGF-1 is broken down in the brain, and is thought to restore synapse function and reduce inflammation.
What the evidence shows
Open-label phase 2 trials by Neuren reported improvements on clinician and caregiver scales. Placebo-controlled confirmation is still needed.
Safety and unknowns
Generally well tolerated in phase 2. Long-term data are limited.
Regulatory status
Not approved. Neuren is moving toward phase 3.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Brain & sleep
Noopept
Wellness and performanceA dipeptide-like compound developed in Russia and sold as a memory aid.
P21
Wellness and performanceA small peptide based on ciliary neurotrophic factor, studied in mice for memory and neurogenesis.
Nerinetide
In clinical trialsA 20 amino acid peptide tested to protect brain cells during stroke.
General information, not medical advice. Do not buy or inject unregulated peptides.